Acutaas Chemicals Ltd (ACUTAAS)
🎯 Key Takeaways
- Acutaas Chemicals Ltd is in a high-growth phase, transitioning from a pharma intermediates-focused business to a diversified specialty chemicals leader with expanding exposure to high-margin segments like battery chemicals and semiconductor additives. The company is executing a clear capital allocation strategy to scale strategic initiatives while maintaining strong returns on capital.
- Revenue declined 23.8% QoQ to ₹330 in Q1FY27.
- ⚠️ High valuation (P/E of 66.8) may limit upside if growth moderates.
- Market Cap
- ₹26,308
- P/E Ratio
- 68.1
- P/B Ratio
- 15.91
- ROE
- 23.4%
- ROCE
- 31.5%
- Debt/Equity
- 0.02
- Div Yield
- 0.08%
- Promoter
- 32.7%
📖 The Story
Acutaas Chemicals Ltd is in a high-growth phase, transitioning from a pharma intermediates-focused business to a diversified specialty chemicals leader with expanding exposure to high-margin segments like battery chemicals and semiconductor additives. The company is executing a clear capital allocation strategy to scale strategic initiatives while maintaining strong returns on capital.
📰 What's Happening
In Q1 FY27 (July 2026), Acutaas reported revenue of ₹3,297 crores, up 59.1% YoY, driven by robust growth in pharma intermediates and specialty chemicals, with PAT rising 70.4% YoY to ₹750 crores. EBITDA margin expanded to 34.3% from 24.6% YoY, reflecting improved product mix and operational efficiencies. Management reaffirmed full-year revenue growth guidance of 25% with stable margins. The company also proposed a final dividend of ₹2.50 per share for FY25-26, contingent on AGM approval on September 24, 2026, with record date set for September 17, 2026. Additionally, it plans to invest ₹1,983 million in capex through FY30 to expand semiconductor chemicals capacity and commercialize two new battery additives products in FY27.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 306 | 393 | 433 | 330 |
| Operating Profit | 87 | 141 | 174 | 103 |
| OPM % | 28.4% | 35.8% | 40.2% | 31.3% |
| Net Profit | 72 | 106 | 134 | 75 |
| EPS | ₹8.82 | ₹13.19 | ₹16.09 | ₹9.07 |
Quarterly financials show accelerating revenue growth, with sequential growth in revenue and profitability from ₹306 crores (Sep 2025) to ₹3,297 crores (Jun 2026), despite minor fluctuations in quarterly revenue. EBITDA margin expansion and rising PAT margins (22.7% in Q1 FY27) indicate improving operational leverage. PAT growth consistently outpaced revenue growth, suggesting effective cost management and margin accretion. The company maintains a strong balance sheet with negligible debt (D/E of 0.01) and rising equity and reserves, supporting its growth investments.
🔮 Management Outlook & What's Next
Management reaffirmed 25% full-year revenue growth guidance with stable margins in Q1 FY27, signaling confidence in sustained momentum. The strategic focus is on scaling high-growth segments including battery chemicals (2,000 MTPA capacity), semiconductor additives via a South Korean JV, and pharma intermediates. Capex of ₹1,983 million is planned through FY30 to support capacity expansion in these areas. Sustainability targets include science-based emission reduction goals to be submitted within 12-18 months, with ongoing expansion of solar capacity and ESG reporting rigor.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 41 | 41 | 41 | 41 |
| Reserves | 1,269 | 1,161 | 1,613 | 1,373 |
| Borrowings | 8 | 6 | 36 | 8 |
| Total Liabilities | 1,549 | 1,427 | 1,984 | 1,696 |
| Fixed Assets | 570 | 355 | 633 | 620 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 1,549 | 1,427 | 1,984 | 1,696 |
The balance sheet shows a stable capital structure with equity of ₹41 crores and reserves growing from ₹1,269 crores (Mar 2025) to ₹1,613 crores (Mar 2026), reflecting retained earnings and reinvestment. Borrowings remain minimal at ₹36 crores (Mar 2026), up slightly from ₹8 crores, indicating limited reliance on debt. Total assets have grown steadily to ₹1,984 crores, supporting expansion without significant leverage increase. This suggests a conservative and self-funded growth model, with retained profits financing most strategic initiatives.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +118 |
| Investing | -224 |
| Financing | +261 |
| Net Cash Flow | +156 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 32.7% | 32.7% | 32.7% | 32.7% |
| FII | 16.9% | 16.7% | 19.5% | 21.6% |
| DII | 22.6% | 21.7% | 19.6% | 19.6% |
| Public | 22.8% | 23.5% | 23.2% | 21.7% |
| # Shareholders | 1,08,664 | 1,10,363 | 1,12,939 | 1,25,569 |
Institutional investor interest has declined slightly, with FII holdings falling from 21.61% (Q1FY27) to 19.48% (Q4FY26), while DII holdings remained relatively stable around 19-22%. Promoter holding remains steady at 32.66%. The number of public shareholders has increased to 1,25,569 (Q1FY27) from 1,08,664 (Q2FY26), indicating broader retail participation. No pledging or significant dilution is evident, and the stable promoter stake suggests confidence in long-term prospects.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. High valuation (P/E of 66.8) may limit upside if growth moderates. 2. PAT growth outpacing revenue could indicate tax rate volatility or one-time gains, which may not be sustainable. 3. Capex intensity through FY30 may pressure cash flows if execution slips. 4. Dependence on global demand for battery and semiconductor chemicals exposes the company to cyclicality and geopolitical risks.
📋 Recent Filings
- 🟡 voting results2026-09-26At the 19th Annual General Meeting on September 24, 2026, ACUTAAS CHEMICALS LIMITED passed all resolutions except Resolution No. 7, which failed to ac…
- 🟡 Board Meeting2026-09-26At the September 24, 2026 Annual General Meeting, shareholders reappointed Mr. Ram Mohan Lokhande as Whole Time Director for five years from February …
- 🔴 Corporate Action2026-09-24Acutaas Chemicals announced approval to acquire 100% of Enchem Ami Organics Private Limited, a step-down subsidiary, through a cashless share swap at …
- 🟡 Board Meeting2026-09-24At the 19th AGM on September 24, 2026, shareholders approved the audited standalone and consolidated financial statements for FY2025-26, declared a fi…
- 🔴 Announcement2026-09-22Acutaas Chemicals announced its investor conference schedule on September 22, 2026, featuring a September 28 meeting with PL Capital focused on growth…
- Announcement2026-09-22Acutaas Chemicals Ltd announced the closure of its insider trading window effective October 1, 2026, ahead of reporting unaudited Q2 and H1 2026 finan…
- 🔴 Announcement2026-09-10Acutaas Chemicals announced that the Indian Patent Office granted it a 20-year process patent for 'A PROCESS FOR PREPARING 2,4-DIMETHYLTHIOPHENOL' on …
- 🔴 Announcement2026-09-04Acutaas Chemicals announced the inauguration of a new pilot plant at its Surat facility on September 4, 2026, designed to support R&D for high-potency…
- 🟡 Board Meeting2026-08-29Acutaas Chemicals Limited announced its 19th AGM on September 24, 2026, via video conference, seeking shareholder approval for key governance and fina…
- 🟡 sustainability report2026-08-29Acutaas Chemicals Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 on August 29, 2026, aligning with SEBI…
🧠 Analyst's Read
Acutaas Chemicals is executing a well-capitalized growth strategy with strong financial momentum and strategic diversification into high-value chemical segments. Investors should monitor execution of capex plans, margin sustainability, and global demand trends in battery and semiconductor markets as key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ACUTAAS files new disclosures
Track ACUTAAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ACUTAAS — FreeFree account · 2 AI queries/day